ATE432716T1 - Verfahren zur behandlung von hepatozellulärem karzinom - Google Patents
Verfahren zur behandlung von hepatozellulärem karzinomInfo
- Publication number
- ATE432716T1 ATE432716T1 AT04777732T AT04777732T ATE432716T1 AT E432716 T1 ATE432716 T1 AT E432716T1 AT 04777732 T AT04777732 T AT 04777732T AT 04777732 T AT04777732 T AT 04777732T AT E432716 T1 ATE432716 T1 AT E432716T1
- Authority
- AT
- Austria
- Prior art keywords
- zvegf3
- hepatocellular carcinoma
- treating hepatocellular
- mammal
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 title abstract 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49004703P | 2003-07-25 | 2003-07-25 | |
| PCT/US2004/021835 WO2005011742A1 (en) | 2003-07-25 | 2004-07-09 | Method of treating hepatocellular carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE432716T1 true ATE432716T1 (de) | 2009-06-15 |
Family
ID=34115347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04777732T ATE432716T1 (de) | 2003-07-25 | 2004-07-09 | Verfahren zur behandlung von hepatozellulärem karzinom |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20050191304A1 (enExample) |
| EP (1) | EP1660135B1 (enExample) |
| JP (1) | JP4709145B2 (enExample) |
| AT (1) | ATE432716T1 (enExample) |
| CA (1) | CA2529798C (enExample) |
| DE (1) | DE602004021395D1 (enExample) |
| DK (1) | DK1660135T3 (enExample) |
| ES (1) | ES2326978T3 (enExample) |
| WO (1) | WO2005011742A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6893637B1 (en) * | 1999-10-21 | 2005-05-17 | Zymogenetics, Inc. | Method of treating fibrosis |
| US9884910B2 (en) * | 2012-04-24 | 2018-02-06 | Thrombogenics Nv | Anti-PDGF-C antibodies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6432673B1 (en) * | 1998-12-07 | 2002-08-13 | Zymogenetics, Inc. | Growth factor homolog ZVEGF3 |
| DK1137773T3 (da) * | 1998-12-07 | 2008-12-08 | Zymogenetics Inc | Væsktfaktorhomolog ZVEGF3 |
| US6893637B1 (en) * | 1999-10-21 | 2005-05-17 | Zymogenetics, Inc. | Method of treating fibrosis |
-
2004
- 2004-07-09 ES ES04777732T patent/ES2326978T3/es not_active Expired - Lifetime
- 2004-07-09 WO PCT/US2004/021835 patent/WO2005011742A1/en not_active Ceased
- 2004-07-09 DK DK04777732T patent/DK1660135T3/da active
- 2004-07-09 CA CA2529798A patent/CA2529798C/en not_active Expired - Fee Related
- 2004-07-09 DE DE602004021395T patent/DE602004021395D1/de not_active Expired - Lifetime
- 2004-07-09 AT AT04777732T patent/ATE432716T1/de active
- 2004-07-09 EP EP04777732A patent/EP1660135B1/en not_active Expired - Lifetime
- 2004-07-09 JP JP2006521860A patent/JP4709145B2/ja not_active Expired - Fee Related
- 2004-07-09 US US10/888,610 patent/US20050191304A1/en not_active Abandoned
-
2006
- 2006-10-24 US US11/552,228 patent/US20070054858A1/en not_active Abandoned
-
2008
- 2008-09-10 US US12/207,647 patent/US20090028865A1/en not_active Abandoned
-
2010
- 2010-03-23 US US12/729,941 patent/US20110052588A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006528663A (ja) | 2006-12-21 |
| DK1660135T3 (da) | 2009-09-07 |
| US20090028865A1 (en) | 2009-01-29 |
| WO2005011742A1 (en) | 2005-02-10 |
| US20050191304A1 (en) | 2005-09-01 |
| US20110052588A1 (en) | 2011-03-03 |
| DE602004021395D1 (de) | 2009-07-16 |
| CA2529798C (en) | 2014-09-16 |
| CA2529798A1 (en) | 2005-02-10 |
| US20070054858A1 (en) | 2007-03-08 |
| EP1660135A1 (en) | 2006-05-31 |
| EP1660135B1 (en) | 2009-06-03 |
| JP4709145B2 (ja) | 2011-06-22 |
| ES2326978T3 (es) | 2009-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1638586T3 (da) | Synergistisk sammensætning til behandling af diabetes mellitus | |
| BRPI0510170B8 (pt) | composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto | |
| ATE314062T1 (de) | Zusammensetzungen zur abgabe von cortisolantagonisten | |
| DE60234183D1 (de) | Verwendung von methylnaltrexon zur behandlung von immunsuppression | |
| DE69925024D1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
| ZA200607224B (en) | Tamper resistant dosage form comprising an adsorbent and an adverse agent | |
| DE60038290D1 (de) | Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen | |
| FR13C0062I1 (enExample) | ||
| WO2006018024A3 (en) | Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists | |
| ATE364595T1 (de) | Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika | |
| ATE496892T1 (de) | Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen | |
| IS8105A (is) | Lyfjablanda sem felur í sér ónæmisbæli til að nota í meðhöndlun á húðsjúkdómum | |
| ATE394104T1 (de) | Adenosin a2a rezeptor-antagonisten zur behandlung und vorbeugung von leberfibrose, zirrhose und fettleber | |
| WO2005011590A3 (en) | Compositions and methods for restoring sensitivity to treatment with her2 antagonists | |
| DK1207870T3 (da) | Farmaceutiske præparater, der indeholder N-palmitoylethanolamid og anvendelse deraf | |
| WO2006065722A3 (en) | Compositions and methods for pulmonary conditions | |
| EP1553449A4 (en) | ACTIVE-ENERGY-FRACTIVE RESIN COMPOSITION, ACTIVE-RESTRICTIVE-RESISTANT RESIN-FILM AND METHOD FOR PRODUCING A STRUCTURE USING THE FILM | |
| ATE465735T1 (de) | Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen | |
| WO2003051290A3 (en) | Treating b-cell mediated diseases by modulating dr6 activity | |
| EP1781629A4 (en) | BENZAMIDINE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | |
| ATE432716T1 (de) | Verfahren zur behandlung von hepatozellulärem karzinom | |
| DE60121047D1 (de) | Pharmazeutische zusammensetzung zur behandlung von phimose mit einem topischen corticosteroid | |
| SE0001373D0 (sv) | NPY Y1 receptor agonists and antagonists | |
| WO2006041769A3 (en) | Methods for the treatment of substance abuse and addiction | |
| WO2004039961A3 (en) | Trefoil domain-containing polypeptides and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1660135 Country of ref document: EP |